The seven-row TL;DR
For each dimension where one drug clearly wins, we name the winner. Where the answer is "depends on your situation," the verdict text below the table explains why.
| Dimension | What the data says | Winner |
|---|---|---|
| FDA-approved for | Diabetes (Ozempic) vs weight loss (Wegovy) | Wegovy |
| Maximum dose | Ozempic 2.0mg vs Wegovy 2.4mg weekly | Wegovy |
| Trial weight loss at max dose | Ozempic 6-7% vs Wegovy 14.9% (different studies) | Wegovy |
| Insurance coverage for weight loss | Wegovy with PA; Ozempic typically not covered for off-label weight loss | Wegovy |
| Cash price | NovoCare runs both; pricing similar at equivalent doses | Tie |
| Real-world availability | Both widely stocked at 2026 supply levels | Tie |
Verdict
If you're seeking GLP-1 medication for weight loss without diabetes, Wegovy is the right answer. It has the indication, the dose range optimized for weight loss, and the insurance pathway. Ozempic for off-label weight loss made sense in 2021-2022 when Wegovy was in shortage; in 2026 it's almost always a worse choice because insurance treats it as off-label. If you have type 2 diabetes, Ozempic is the indicated option and your insurance pathway is straightforward.
Trial efficacy compared
The headline numbers are not from the same study, so direct comparison is approximate. The 2024 SURMOUNT-5 trial directly compared tirzepatide to semaglutide and found tirzepatide produced greater weight loss across all dose comparisons, validating the cross-trial signal.
| Ozempic | Wegovy | |
|---|---|---|
| Registration trial | SUSTAIN-6 (NEJM, 2016) | STEP-1 (NEJM, 2021) |
| Duration | 104 weeks | 68 weeks |
| Mean weight loss (max dose) | 6.5% | 14.9% |
| Effect vs placebo | 3.6 pp | 12.4 pp |
| Patients losing ≥5% | 47.0% | 86.4% |
| Patients losing ≥15% | 13.0% | 50.5% |
2026 cash-pay cost compared
Both manufacturers run direct-to-consumer cash channels (NovoCare for Ozempic, LillyDirect for Wegovy) which are dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.
| Channel | Ozempic | Wegovy |
|---|---|---|
| Retail cash | $998/mo | $1,349/mo |
| Manufacturer DTC | $499-$899/mo via NovoCare (dose-tier dependent) | $199-$499/mo via NovoCare |
| With insurance + PA | $25-$50/mo with diabetes diagnosis and prior authorization | $25-$50/mo with prior authorization |
| Compounded | $99-$249/mo via 503A pharmacies (same active ingredient as Wegovy) | $99-$249/mo via 503A pharmacies |
When to choose Ozempic
Choose Ozempic if: (1) you have type 2 diabetes (it is the indicated option); (2) your insurance covers Ozempic but not Wegovy on its formulary (this still happens with some employer plans); (3) you previously titrated up to Ozempic 2.0mg and it works for you; you do not need the higher Wegovy 2.4mg.
When to choose Wegovy
Choose Wegovy if: (1) you do not have diabetes and want GLP-1 for weight loss (Wegovy is the indicated option, Ozempic is off-label); (2) you want access to the higher 2.4mg dose; (3) you want the cleanest insurance prior authorization pathway. Wegovy's PA approval rates for obesity (BMI ≥30 or BMI ≥27 with comorbidity) are well-documented; Ozempic for off-label weight loss is rarely covered.
Programs that prescribe each
Top Ozempic programs
Top Wegovy programs
FAQ
Are Ozempic and Wegovy the same drug?
Can I get Ozempic for weight loss?
Can I switch from Ozempic to Wegovy?
Why is Wegovy more expensive at retail?
Read the full drug profiles
Editorial disclosure
GLP Chart is an editorial comparison site. We do not dispense, prescribe, or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of 12 May 2026. Talk to a licensed clinician about which medication is appropriate for you.